Founded with a mission to revolutionize pet healthcare, LEAH Labs focuses on engineering living therapies for pets, particularly targeting cancer. Utilizing virus-free gene editing technology, the company aims to develop CAR-T cell therapy for dogs, addressing an unmet need in companion animal medicine while also creating a platform to discover and de-risk potential human treatments. Their market focus includes pet owners and veterinary professionals, with a particular emphasis on treating B cell lymphoma in dogs.
Notable affiliations include partnerships with the University of Minnesota, Ohio State University, University of Missouri, and North Carolina State University. LEAH Labs has achieved significant milestones, such as enrolling pet patients in fully funded pilot efficacy trials. By pioneering CAR-T cell therapy for pets, the company not only enhances veterinary care but also contributes valuable insights to human medical research, creating a profound impact on both fields.
